The activities of the N-(nitrothiazolyl) salicylamide nitazoxanide and its metabolite tizoxanide were compared with metronidazole in vitro in microplates against six axenic isolates of Giardia intestinalis. Tizoxanide was eight times more active than metronidazole against metronidazolesusceptible isolates and twice as active against a resistant isolate. In 10 axenic isolates of Entamoeba histolytica, while tizoxanide was almost twice as active as metronidazole against more susceptible isolates, it was more than twice as active against less susceptible isolates. Fourteen metronidazole-susceptible isolates of Trichomonas vaginalis were 1.5 times more susceptible to tizoxanide, which was nearly five times as active against resistant isolates. Two highly metronidazole-resistant isolates retained complete susceptibility to tizoxanide, and one moderately resistant isolate showed reduced susceptibility. In all three organisms, nitazoxanide results paralleled those of tizoxanide. Analogues lacking the reducible nitro-group had similar low activities against susceptible G. intestinalis, E. histolytica and T. vaginalis, indicating that nitro-reduction and free radical production was a probable mode of action. Nitazoxanide and its metabolite tizoxanide are more active in vitro than metronidazole against G. intestinalis, E. histolytica and T. vaginalis. Although, like metronidazole, they depend on the presence of a nitro-group for activity, they retain some activity against metronidazole-resistant strains, particularly of T. vaginalis. The results suggest that resistance mechanisms for metronidazole can be bypassed by nitazoxanide and tizoxanide.
Introduction
Metronidazole, a 5-nitroimidazole drug, is the treatment of choice for intestinal disease caused by the flagellate Giardia intestinalis and the amoeba Entamoeba histolytica and for vaginitis caused by the flagellate Trichomonas vaginalis. 1 Although failure following metronidazole therapy has been reported in some cases of liver abscess due to E. histolytica, 2 resistance has not yet been proven in strains isolated from patients. In contrast, proven cases of metronidazole resistance in G. intestinalis and T. vaginalis have been documented. 3, 4 Should resistance to metronidazole or its analogues become widespread, new active compounds will be needed. This is especially relevant for T. vaginalis, which may be associated with increased HIV transmission. 5 The objective of this work was to evaluate in vitro the activities of an N-(nitrothiazolyl) salicylamide, nitazoxanide 6 [2-acetyloxy-N-(5-nitro 2-thiazolyl) benzamide] ( Figure) , and its metabolites, 7, 8 in comparison with metronidazole against isolates of G. intestinalis, E. histolytica and T. vaginalis, and to make a preliminary assessment of its mode of action. Nitazoxanide was designed for broad-spectrum antiparasitic activity and low toxicity. It is active against the coccidian protozoan Cryptosporidium parvum in cell culture and in mice and piglets, [9] [10] [11] the microsporans Encephalitozoon intestinalis and Vittaforma corneae in cell culture, 12 the helminths Syphacia obvelata and Hymenolepis nana in mice 13 and Taenia pisiformis, Uncinaria stenocephala and Trichuris vulpis in dogs. 14 In vitro studies have also shown a broad range of antimicrobial activity against facultative or obligate anaerobic and microaerophilic Gram-positive and Gram-negative bacteria 15 including Helicobacter pylori. 16 Clinical trials carried out in North and South America, Western Europe, the Middle East and Africa in more than 1500 patients have reported the effect of nitazoxanide on infections with C. parvum, 17, 18 the microsporan Enterocytozoon bieneusi, 19 E. histolytica, Following a single oral dose of [ 14 C]nitazoxanide 500 mg in humans, 32% of the radioactivity was recovered in the urine and 66% in the faeces, indicating significant absorption from the gastrointestinal tract. The parent drug, nitazoxanide, is not found in blood, urine or faeces, but is presumably present to some extent in the contents of the intestine. The two major metabolites are produced by hydrolysis and glucurono conjugation; desacetyl-nitazoxanide (tizoxanide) is found in faeces, plasma and urine and tizoxanide glucuronide in plasma, urine and bile. The maximum concentration of tizoxanide in plasma following an oral dose of [ 14 C]nitazoxanide 500 mg was c. 2 mg/L (6.5 M), and its half-life in plasma was c. 1-2 h. Minor metabolites include salicyluric acid, tizoxanide sulphate and traces of hydroxytizoxanide in urine. Salicylate is found in faeces. 8 Tizoxanide and to some extent nitazoxanide probably account for activity in the intestine, while in other locations tizoxanide may be the most important agent. However, high concentrations of tizoxanide glucuronide are excreted in bile, 8 and the action of this compound may be manifested on liver trematodes such as F. hepatica.
In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis

Materials and methods
Sources of strains of protozoa
Strains of G. intestinalis (VNB1, VNB2, VNB5, EBC and EBE) were isolated from patients' faecal samples in London. 23 The last two strains were used with the agreement of Prof. John P. Ackers [London School of Hygiene and Tropical Medicine (LSHTM)]. The strains were isolated from diagnostic faecal samples from cases of giardiasis returning from the Indian subcontinent, subsequently successfully treated with metronidazole. All of these strains were determined by us to be susceptible to metronidazole in vitro. A further isolate of G. intestinalis (JKH-1) was isolated from a chronic human infection refractory to metronidazole by Dr Tim Paget (University of Hull), and was kindly supplied by him.
Two E. histolytica isolates, HM1:IMSS (Mexico) and NIH200 (Korea), had been held in culture and cryopreservation in the LSHTM laboratory since 1976, when they were supplied to us by the late Dr R. A. Neal (Wellcome Research Laboratories, Beckenham, UK). Isolates IULA: 1092:1 and IULA:0593:2 isolated from amoebic dysentery patients in Venezuela were kindly supplied by Professor John P. Ackers (LSHTM). Other isolates were purchased from the American Type Culture Collection (ATCC). The history and relevant references for the E. histolytica strains used are in Table 1 .
A set of recent isolates of T. vaginalis from cases of vaginitis in Peru before treatment with nitazoxanide was received by air in 'InPouch' cultures. After establishment in continuous culture they were cryopreserved in our laboratory (isolates with 'PER' prefix). The history of the standard strains of T. vaginalis used is in Table 2 .
Antimicrobial agents
The drugs used in the study were obtained as dry powders. Metronidazole was purchased from Sigma-Aldrich (Poole, UK), and nitazoxanide, tizoxanide, tizoxanide glucuronide, denitronitazoxanide and denitrotizoxanide were provided by Romark Laboratories, L.C. (Tampa, FL, USA). 
In vitro studies
Stabilates were recovered from cryopreservation and cultured using Diamond's TYI-S-33 complete medium. 34 Inactivated adult bovine serum was used at 10% and the vitamin-Tween 80 mixture at 3%. The complete medium was supplemented with bile 0.5 g/L (Sigma) for G. intestinalis. 35 Parasites were routinely grown in 12 mL flat-sided plastic test tubes (Nunc) at 35ЊC. Medium was removed from cultures in the log phase of growth showing a monolayer of trophozoites (observed under the inverted microscope); they were then exposed to 10 mL fresh chilled culture medium at 0ЊC on an ice/water bath for 10 min and resuspended. For subculturing, 0.2-0.4 mL of this suspension was transferred to fresh tubes containing culture medium.
For the in vitro drug test the method described by Cedeño & Krogstad 25 for E. histolytica was modified as follows. Stocks of metronidazole, dissolved in water, and tizoxanide, nitazoxanide, tizoxanide glucuronide, denitronitazoxanide and denitrotizoxanide, dissolved in DMSO, were prepared and stored at 4ЊC. Dilutions were made in serum-free culture medium and sterilized through a 0.2 m filter. Final dilutions were made immediately before the test in complete medium to give twice the top concentration to be used for the in vitro testing. Two hundred microlitres of this was transferred to duplicate drug wells (B1-H1, in a flat-bottomed 96-well microtitre test plate) (Corning, New York, USA). Row A, wells 7-12 and rows B-H wells 2-12 received 100 L of complete medium. Two-fold serial dilutions were made from B1-H1 to B12-H12. In row A, wells 1-12 were drug free, and 200 L of complete culture medium was dispensed into wells 1-6 to serve as uninfected controls, while wells 7-12 were inoculated with 100 L of parasite suspension as infected controls. Final concentrations of DMSO required in the tests for nitazoxanide and tizoxanide at IC 50 values were 0.01% (v/v) or lower, and inactive in the assay systems. DMSO alone began to have inhibitory effects at 0.1% (v/v).
Parasite preparation
Healthy growing cultures in the log phase were selected for in vitro drug testing. Medium was carefully decanted, after gentle centrifugation where necessary, and replaced with fresh complete medium. Parasites were resuspended in 5 mL of medium. Twenty microlitres of suspension were fixed by adding 1 L of 2% formalin and counts were made using a haemocytometer. The number of organisms per well varied in preliminary experiments with E. histolytica, the most difficult of the organisms to grow consistently, and we found that 50 000 organisms/mL were needed in order to obtain optimal reproducibility with the range of strains tested. This is similar to the concentration of 30 000/mL found to be optimal by Upcroft et al. 4 for Entamoeba, and in contrast to 6000/mL as used by Cedeño & Krogstad 25 in their work on strain HK9 of E. histolytica.
Dilutions were made in fresh tubes, with complete medium, to give a density of 100 000 organisms/mL and this was transferred in 100 L volumes from a sterile vessel, frequently agitated, to each of wells 7-12 of row A (infected control) and to the test wells of rows B1-H1 to B12-H12. Each well (test and infected control) finally contained 10 000 organisms in a final volume of 200 L of drug-medium-parasite mixture (50 000 organisms/mL) and this system was applied to all three parasites. The final concentration of organisms in the Giardia and Trichomonas cultures is lower than that used by Upcroft et al. 4 
Incubation
The culture plates were placed in an airtight modular incubator chamber (Billups-Rothenberg, CA, USA) that had been swabbed clean with 70% ethanol and humidified with damp tissue treated with cupric sulphate solution (Sigma) to avoid bacterial and fungal contamination. The chamber was gassed for 5 min with a filter-sterilized gas mixture of 3% O 2 , 4% CO 2 and 93% N 2 (a gas phase suitable for microaerophilic organisms and for 'aerobic' tests on T. vaginalis). 36 Incubation was at 35ЊC. After 24 h, plates were viewed on an inverted microscope to monitor parasite growth. Wells were dosed with 5 L of methyl [ 3 H]thymidine solution (Amersham, UK) to a final concentration of 0.2 Ci/well. Culture plates were returned to the chamber, gassed as above and incubated at 35ЊC for a further 24 h. Methyl-[ 3 H]thymidine was obtained as 1 mL aqueous solution with a specific activity of 51 Ci/mmol and total activity of 1 mCi. This was transferred to a sterile Universal tube and vial rinsings added in a total volume of 25 mL serum-free culture medium (40 Ci/mL). This was filtersterilized through a 0.2 m filter and kept at Ϫ20ЊC until needed.
Assessment of drug activity
After addition of the radiolabelled thymidine and 24 h of incubation, plates were chilled at 4ЊC in an ice/water-bath. Parasites were harvested with a cell harvester (Skatron Inc., Liev, Norway) on to glass fibre filter paper (ICN Biomedicals Inc., CA, USA). 37, 38 After drying, the filter discs were punched out into scintillation vials. Three millilitres of scintillation fluid (Ecoscint; National Diagnostics, UK) were added and radioactivity counted (3 min per vial) in a Tricarb liquid scintillation spectrometer (Packard, Meriden, USA). The disintegrations per minute (dpm), representing the incorporation of methyl-[ 3 H]thymidine by surviving parasites, were recorded. Counts from the uninfected control served as 100% inhibition and those from the infected control represented 0% inhibition. The dose-response was analysed using a non-linear regression (Levenberg-Marquardt algorithm) (XLFit programme #1.02, an add-in for Microsoft Excel). The dpm for each well was converted to percentage inhibition, which was plotted as a function of the logarithm of drug concentration. IC 50 s were obtained from the sigmoid curves.
All experiments were performed at least three times in duplicate, and the mean values with standard deviations are given in Tables 3-6 
Results
The results are expressed as molar drug concentrations that were required to obtain a reduction of 50% in tritiated thymidine incorporation into the culture (IC 50 ) as compared with untreated controls.
Six isolates of G. intestinalis (Table 3)
One clearly resistant isolate was three times less susceptible to metronidazole than the mean for the susceptible isolates, and this differential was 13 times for tizoxanide, the active metabolite of nitazoxanide. Tizoxanide was eight times as active against susceptible isolates as metronidazole and twice as active against the resistant isolate. Nitazoxanide results paralleled those of tizoxanide, but for the metabolite tizoxanide glucuronide, which was about onethird as active as metronidazole, there was no detectable difference in activity against the resistant strain (JKH-1). The activity of tizoxanide glucuronide in G. intestinalis VNB1 did not differ from that of denitrotizoxanide (Table  4) . Denitrotizoxanide was 48 times less active than tizoxanide, while denitronitazoxanide was 17 times less active than nitazoxanide (see Table 5 ).
Ten isolates of E. histolytica (see Table 4)
The mean metronidazole IC 50 value for the most susceptible isolates of E. histolytica was 18.47 M, and Ͼ30 M was chosen as the cut-off for 'resistance'. On the basis of literature values this was set at about three times the value for the most susceptible strain. 31 Susceptibility to metronidazole showed a seven-fold range from 9.5 to 65.9 M. On a molar basis, tizoxanide was 1.42 times as active against susceptible isolates as metronidazole, but was Table 5 ). Table 6 )
Seventeen isolates of T. vaginalis (see
The isolates of T. vaginalis used showed a 10-fold range of susceptibility to metronidazole from 0.6 to 60 M. The cutoff for resistance in our study, following the susceptibility designations of the standard strains, was taken as an IC 50 Ͼ 20 M. These strains were still susceptible to tizoxanide. Against metronidazole-resistant isolates, tizoxanide was 4.88 times as active as metronidazole, and 1.39 times as active against susceptible isolates. Nitazoxanide results paralleled those of tizoxanide, but for tizoxanide glucuronide, which was about 0.33 times as active as metronidazole against the susceptible isolates, activity against the resistant strains was 1.93 times higher than metronidazole. Denitrotizoxanide was five times less active against susceptible T. vaginalis PER 014/CGF than tizoxanide, while denitronitazoxanide was 10 times less active than nitazoxanide (Table 4) . Nitazoxanide results paralleled those of tizoxanide.
Discussion
Comparison of different studies is particularly difficult because different methods are used for activity measurement. Some workers use minimal lethal concentration (MLC), some MIC and some IC 50 . The ratio between mean susceptible and resistant values may afford a fair comparison between studies. Upcroft & Upcroft 39 found that the mean MIC value for their strains of metronidazoleresistant G. intestinalis was 7.9 times higher than for susceptible strains (6.3 and 50 M), compared with an IC 50 ratio of 3.1 (4.93 and 15.42 M) for our five susceptible and one resistant strains. For T. vaginalis there is the further complication of aerobic and anaerobic methods of measurement. Our comparison is with the former, which appears more clinically relevant. In metronidazole-susceptible clinical cases of trichomoniasis the isolates showed a geometrical mean aerobic MLC of 24.1 mg/L compared with 195.5 mg/L from drug refractory cases. 33 This is a ratio of eight, which compares with our ratio of mean IC 50 values for susceptible and resistant isolates of 6.22 ( 25 This clone has not, to our knowledge, been tested previously.
In G. intestinalis, tizoxanide was eight times more active than metronidazole against metronidazole-susceptible isolates and twice as active against a resistant isolate. In 10 axenic isolates of E. histolytica tested in the same way, tizoxanide was almost twice as active as metronidazole against more susceptible isolates and was more than twice as active against less susceptible isolates.
In T. vaginalis tizoxanide was 1.5 times as active as metronidazole against susceptible isolates but was nearly five times as active against resistant isolates. In G. intestinalis, E. histolytica and T. vaginalis the glucuronide metabolite of nitazoxanide was 0.3, 0.63 and 0.33 times as active, respectively, as metronidazole in susceptible strains, and was 1.1, 1.59 and 1.9 times as active as metronidazole against resistant strains. The activity of tizoxanide glucuronide is appreciably less than that of tizoxanide and nitazoxanide, and little difference could be found between the resistant and the susceptible strains (Table 5) .
This suggests that the glucuronide may not readily enter the cell to be activated by intracellular reduction. The reductions in tizoxanide activity brought about by removal of the nitro-group and by glucuronidation were remarkably similar within species (Table 5 ). The measured IC 50 concentrations across the species (for denitrotizoxanide, 29.0, 37.0, 32.6 M; for tizoxanide glucuronide, 33.2, 25.9, 19.6 M) are remarkably similar considering the differing IC 50 values for the parent tizoxanide. These observations support the idea that the glucuronide metabolite may not undergo nitro-reduction in these organisms and indicates that intracellular nitro-group reduction is necessary for activity of tizoxanide. The removal of the nitro-group renders reductive activation impossible, but may also have an impact on other properties of the drug, for example the lipophilic character is increased, and the yellow colour is lost, the latter feature indicating a decrease in the degree of conjugation of the ring system. It is however probable that, as with the 5-nitroimidazoles, the reducibility of the nitrogroup is the most important feature involved. 40 Nitazoxanide is active against a wider range of organisms than metronidazole. In addition, metronidazoleresistant strains of H. pylori were susceptible. 16 Since resistance to metronidazole in G. intestinalis and T. vaginalis apparently depends on decreased ability to activate the drug, 41 evidence of some cross-resistance and relative inactivity of denitro-derivatives presented in this paper helps to confirm the probable mode of action. Higher activity than metronidazole seen for nitazoxanide and tizoxanide in relatively metronidazole-refractory strains of all the three organisms studied indicates that resistance mechanisms to metronidazole may be to a variable extent bypassed by nitazoxanide and tizoxanide. This feature may relate to retention of the ability of the metronidazole-resistant organisms to reduce the drug at a less negative redox potential than that required for metronidazole. The redox potential reported for one electron reduction of another 5-nitrothiazole was Ϫ390 mV, much less negative than Ϫ486 mV seen in the 5-nitroimidazole group of metronidazole. 42 The data we have so far on resistant strains are insufficient to draw firm conclusions on the mechanisms of resistance and need further expansion.
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Although the effect of tizoxanide and related agents on C. parvum originally seemed to be anomalous, there is now evidence for an unusual cytosolic pyruvate oxidoreductase resembling pyruvate ferredoxin oxidoreductase,
